38 results about "Leukemia lymphoma" patented technology

The invention relates to the use of arsenic compounds to treat a variety of leukemia, lymphoma and solid tumors. Further, the arsenic compounds may be used in combination with other therapeutic agents, such as a retinoid. The invention also provides a process for producing arsenic trioxide formulations.

The invention provides a reagent composition for leukemia / lymphoma typing. The reagent composition comprises 19 kinds of antibodies. According to the optimized antibody combination, the fluorescence labeling combination of the corresponding antibody and the result interpretation method, the AML, the ALL-B, the ALL-T, the MPAL, the NHL-B, the NHL-T, the PCN, the NHL-NK and the chronic myeloid tumors can be preliminarily screened comprehensively and efficiently only by using 19 antibodies and one-tube cell one-time sample loading, and the aim of clearly diagnosing the AML, the ALL-B, the ALL-T, the MPAL, the NHL-B, the NHL-T and the PCN is achieved. The 19 antibody combinations are used for analyzing the expression of tumor cell antigens in a sample, and leukemia-related immunophenotypes (LAIP) which can be used for monitoring post-treatment trace residual disease (MRD) in the antibody combinations are determined.

The invention belongs to the technical field of antibody medicines and provides two types of antibody compositions including CD45 antibody, CD13 antibody, CD33 antibody and CD7 antibody or including CD45 antibody, CD117 antibody, CD34 antibody and CD19 antibody. The invention further provides a leukemia and lymphoma typing kit comprising the two types of antibody compositions and capable of being used with a flow cytometry to achieve typing of various hematological neoplasms.

The invention relates to an application of a macrolide compound in reversing tumor multidrug resistance and enhancing an anti-tumor curative effect. The compound has the functions of inhibiting ABC transport protein activity, improving the concentration of a substrate chemotherapeutic drug of the ABC transport protein in tumor cells, reversing tumor multidrug resistance, and enhancing curative effects of the ABC transport protein substrate chemotherapeutic drugs such as antibiotic tumor chemotherapeutic drugs, plant-derived tumor chemotherapeutic drugs and small-molecular tyrosine kinase inhibitors, and has an effect of enhancing curative effects when being combined with antitumor drugs. Effective dose of the compound is combined with effective dose of an anti-tumor drug for application, apharmaceutically acceptable compound preparation is prepared by mixing with an effective dose of the antitumor drug, and is used for treating tumors including leukemia, lymphoma, gastric cancer, colon cancer, liver cancer, pancreatic cancer, breast cancer, nasopharyngeal carcinoma, cervical carcinoma, melanoma, multiple myeloma, and sarcoma.

The present invention provides a method of combination therapy comprising administration of a tissue-targeting radio-pharmaceutical and a DNA-repair inhibitor. The method may be used in the treatment of hyperplastic or neoplastic disease, such as a carcinoma, sarcoma, myeloma, leukemia, lymphoma or mixed type cancer.

The invention belongs to the technical field of antibodies, and provides an antibody composition composed of ten antibodies, wherein the tan antibodies comprises CD71 resistant antibody, CD7 resistant antibody, CD13 resistant antibody, CD33 resistant antibody, CD19 resistant antibody, CD117 resistant antibody, CD34 resistant antibody, CD10 resistant antibody, HLA-DR resistant antibody, and CD45 resistant antibody. The invention provides a leukemia-lymphomas primary screening kit containing the antibodies, and the application thereof.

The invention discloses application of scutellarein in preparing angiogenesis treatment medicines, and belongs to the field of pharmacy. Experimental study proves that the scutellarein has higher angiogenesis inhibition function, and has exact prevention and treatment functions on angiogenesis-related diseases such as tumor, leukemia, lymphoma and hemangioma angiogenesis, benign angiogenesis, arthritis diseased tissue angiogenesis, eye diseased tissue angiogenesis and the like, and meanwhile, the scutellarein also has remarkable inhibition on stigmatization during wound healing. The scutellarein can directly act on endothelial cells of vessels, has small administration dosage and high clinical effect during clinical application, side effects are small, and drug resistance is not generated easily.

The invention provides a chimeric antigen receptor. The chimeric antigen receptor comprises an extracellular structural domain, a transmembrane structural domain and an intracellular structural domainwhich are connected in sequence, wherein the extracellular structural domain comprises an antigen recognition region and a hinge region; and one end of the intracellular structural domain, which is connected with the transmembrane structural domain, is connected with a CD3 epsilon intracellular region. The chimeric antigen receptor provided by the invention can further improve the treatment effect of B-cell leukemia lymphoma in B-cell leukemia lymphoma treatment, and reduces inflammatory cytokines generated by macrophage monocyte activation by down-regulating cytokines of the chimeric antigenreceptor, so that cytokine storm can be prevented at an early stage, and the risk of neurotoxicity can be reduced. The treatment effect of solid tumors with high mesothelin expression is further improved in mesothelin positive tumor treatment, and meanwhile, cytokine storm can be prevented in an early stage and the risk of neurotoxicity can be reduced.

The present invention pertains to the use of subunits and oligomers of mannan- binding lectin (MBL) in prophylactic and / or curative treatment of an immunocompromised individual such as subjects suffering from solid tumors or haematological cancers. Solid tumors include such as female cancers, male cancers, cancers of the respiratory system, cancers of the gastro intestinal system, the renal system and further subjects suffering from thyroid cancer and melanomas. Haematological cancers include leukaemia, lymphoma and myeloma. The immunocompromised condition of the individual may be due to a cancer disease as mentioned herein or the treatment of said cancer disease.

The present invention relates to derivatives of benzimidazoles of formula (I) as disclosed herein as well as pharmaceutical compositions comprising said derivatives. The derivates according to the present invention are serine / threonine and tyrosine kinase-inhibitors, particularly of PIM1-3- and DYRK1A-kinases and may particularly be used in the treatment of diseases linked to these kinases, such as e.g. leukemias, lymphomas, solid tumors and autoimmune disorders.

The invention belongs to the technical field of antibody medicines and provides two types of antibody compositions including CD45 antibody, CD13 antibody, CD33 antibody and CD7 antibody or including CD45 antibody, CD117 antibody, CD34 antibody and CD19 antibody. The invention further provides a leukemia and lymphoma typing kit comprising the two types of antibody compositions and capable of being used with a flow cytometry to achieve typing of various hematological neoplasms.

Cancers, particularly solid tumors (e.g., breast, lung, renal, colon and ovarian cancers and melanomas) and cancers of the hematologic system, e.g., hemopoietic cancers such as leukemias, lymphomas or myelomas, are treated by administration of a therapeutically effective amount of a compound having the formula (1): (I)in which the quinoline ring is substituted by from one to three groups selected from halogen and trifluoromethyl (designated in the formula by “A”), and is optionally further substituted by one or more other moieties and R is (a) NR1R2 in which R1 and R2 are independently hydrogen or C1-C4 alkyl; (b) 2-piperidyl, (c) 2-pyridyl, and (d) 5-(ethyl or vinyl)-quinuclidin-4-yl; an enantiomer of such a compound; a pharmaceutically acceptable salts of such a compound or of an enantiomer thereof; a prodrug of such a compound or of an enantiomer thereof; a metabolite of such a compound or of an enantiomer thereof; and mixtures of two or more of the foregoing. A particularly preferred compound is mefloquine.

A pharmaceutical composition containing an anti-proliferative compound, named Tecomaphorbide, which is identified and isolated from Tecoma plants (e.g. Tecoma stans). The pharmaceutical composition may contain a derivative and / or a salt of Tecomaphorbide. A process of obtaining Tecomaphorbide from Tecoma plants is specified. A method of treating cancer (e.g. leukemia, lymphoma, breast, colon, and prostate cancer) with the pharmaceutical composition is also provided.

A pharmaceutical composition containing an anti-proliferative compound, named Tecomaphorbide, which is identified and isolated from Tecoma plants (e.g. Tecoma stans). The pharmaceutical composition may contain a derivative and / or a salt of Tecomaphorbide. A process of obtaining Tecomaphorbide from Tecoma plants is specified. A method of treating cancer (e.g. leukemia, lymphoma, breast, colon, and prostate cancer) with the pharmaceutical composition is also provided.

The invention discloses an application of 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1H-indole-3-yl) ethanone or pharmaceutically acceptable salt thereof in preparation ofa medicine for treating or preventing tumor diseases. The product is used for relieving and / or adjunctively treating and / or treating myeloma, leukemia, lymphoma, pancreatic cancer, gastric cancer, breast cancer, ovarian cancer, lung cancer, liver cancer, skin cancer, rectal cancer, prostate cancer, thyroid cancer and other tumors. The 1-(5-(3-((4-chlorobenzyl) amino)-2-hydroxypropoxy)-2-methyl-1-(p-tolyl)-1 hydrogen-indole-3-yl) ethanone has a remarkable specific inhibition effect on PI3K gamma (polyisocyanurate).

The invention belongs to the technical field of pharmacy, and relates to an application of small molecule compounds ZINC5921027 and ZINC1413516 in preparation of human La protein inhibitors, in particular to an application in preparation of drugs for preventing, delaying or treating high-expression human La protein participated or mediated diseases. The small molecule compound can be effectively combined with human La protein, inhibits the most basic biological function of the La protein, and plays a role of a human La protein inhibitor. The prepared human La protein inhibitor is suitable for treating malignant tumors participated or mediated by a high La protein expression pathway and diseases secondary to increase of virus replication participated or mediated by the high La protein expression pathway. The malignant tumors comprise ovarian cancer, cervical cancer, endometrial cancer, breast cancer, liver cancer, head and neck lymphocyte cancer, oral lymphocyte cancer, leukemia, lymphoma and the like. Diseases secondary to the increased virus replication include hepatitis B, hepatitis C and herpes simplex.

The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia / lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.

The present invention relates to the diagnostic of CMMRD. In the present work, the inventors aimed to develop a test that could drastically simplify and improve the diagnosis of CMMRD based on DNA sequence analysis of primary blood cells (PBCs) from patients. Using massive parallel sequencing, they explored the possibility that MSI, the main genomic and functional consequence of constitutive MMR-deficiency, was likely to occur in CMMRD PBCs well before any transformation. Thus the present invention relates to a method of diagnosing a CMMRD cancer or a MSI leukemia / lymphoma in a patient in need thereof.

Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to Globo H, stage-specific embryonic antigen 3 (SSEA-3) and stage-specific embryonic antigen 4 (SSEA-4)are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cellsurfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as sarcoma, skin cancer, leukemia, lymphoma, brain cancer, glioblastoma, lung cancer, breast cancer, oral cancer, head-and-neck cancer, nasopharyngeal cancer, esophagus cancer, stomach cancer, liver cancer, bile duct cancer, gallbladder cancer, bladder cancer, pancreatic cancer, intestinal cancer, colorectal cancer, kidney cancer, cervix cancer, endometrial cancer, ovarian cancer, testical cancer, buccal cancer, oropharyngeal cancer, laryngeal cancer and prostate cancer.

The present invention proposes a compound represented by formula (I) or a pharmaceutically acceptable salt or prodrug thereof. The compound has a novel structure, high efficiency and low toxicity, and has excellent CXCR4 antagonistic activity, which can block HIV from invading and infecting human target cells or treat or prevent AIDS or mobilize human bone marrow hematopoietic cells, mesenchymal stem cells and stem cells or interfere with CXCL12 / CXCR4-mediated Cell migration and adhesion or prevention, treatment of tumor metastasis, invasion and growth mediated by CXCR4 or block CXCL12 / CXCR4 mediated autoimmunity and inflammatory response; and this type of compound can be used as an effective drug in the pharmaceutical composition The components can be used in combination with other anti-HIV drugs to prevent and treat HIV or in combination with other drugs used for treatment or prevention of leukemia, lymphoma, myeloma and solid tumors to prevent and treat tumors.

The present invention provides compositions comprising a 3′-OH, 5′-OH, chemically unmodified, synthetic phosphodiester nucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 4, and a pharmaceutically acceptable carrier, wherein the compositions are useful to induce differentiation of cells or to stimulate differentiation or production of pluripotent cells. The present invention provides methods of using these compositions to induce differentiation of pluripotent cells, including bone marrow derived cells, and to treat disease associated with insufficient differentiation of cells in animals and humans, including but not limited to leukemia, lymphoma, non-malignant blood disorders such as hemoglobinopathies, sickle cell disease, myelodysplastic syndrome, pancytopenia, anemia, thrombocytopenia and leukopenia.

The present application relates to treatment of a hematological disease selected from leukemia, lymphoma, and multiple myeloma in a patient in need thereof, comprising administering to the patient: (a) a therapeutically effective amount of a selective JAK1 inhibitor; (b) a therapeutically effective amount of an immunomodulatory agent, and (c) a therapeutically effective amount of a steroid.

The invention discloses an automatic cerebrospinal fluid cell analysis system based on artificial intelligence. The system comprises an establishment method of a cerebrospinal fluid cell image featurelibrary, a cerebrospinal fluid cell image feature acquisition method and device, and an automatic cerebrospinal fluid cell image identification and counting method. The invention overcomes the defects in the prior art, and provides a cerebrospinal fluid cell image library establishment method, a cerebrospinal fluid cell image acquisition method and device, and a cerebrospinal fluid cell image automatic identification and counting method. Feature extraction is automatically carried out on a cerebrospinal fluid cell image, pixel-level segmentation is carried out on cerebrospinal fluid cells, the segmented cerebrospinal fluid cells are classified, and cells of the whole cerebrospinal fluid cell image are counted. According to the invention, the working efficiency of brain cell detection is greatly improved, the labor intensity of workers is reduced, and an important cerebrospinal fluid cell detection means is provided for the diagnosis of diseases such as central nervous system infection, meningeal leukemia, lymphoma, cerebral parasitic diseases, cerebrovascular diseases, immune degeneration and the like.

De-ethylflavopereirine, a pharmaceutically acceptable salt thereof, a solvate or a hydrate thereof, or a pharmaceutically acceptable salt of a solvate or a hydrate thereof may be used as cancer therapy (i.e., prevention and / or treatment) in a subject in need thereof, including a pathological condition such as inflammation, especially chronic, or cancer (e.g., a carcinoma, a sarcoma, a melanoma, a leukemia, a lymphoma), especially a solid tumor and / or a metastasis thereof. In particular, systemic administration of such improved anti-cancer agents in effective amounts may selectively destroy cancer cells (including cancer stem cells) in a solid tumor and / or at a site of metastasis. They are well-tolerated by the subject, even at large systemic doses and their resulting high concentrations in the circulation, and provide safe and effective anti-cancer agents.

The invention belongs to the technical field of antibodies, and provides an antibody composition composed of ten antibodies, wherein the tan antibodies comprises CD71 resistant antibody, CD7 resistant antibody, CD13 resistant antibody, CD33 resistant antibody, CD19 resistant antibody, CD117 resistant antibody, CD34 resistant antibody, CD10 resistant antibody, HLA-DR resistant antibody, and CD45 resistant antibody. The invention provides a leukemia-lymphomas primary screening kit containing the antibodies, and the application thereof.

The invention relates to the application of a macrocyclic lactone compound in reversing multi-drug resistance of tumors and enhancing anti-tumor curative effect. The compound can inhibit the activity of ABC transporter and increase the concentration of chemotherapeutic drugs which are substrates of ABC transporter in tumor cells. Reverse tumor multidrug resistance, enhance the curative effect of antibiotic tumor chemotherapeutic drugs, plant-derived tumor chemotherapeutic drugs and small molecule tyrosine kinase inhibitors and other ABC transporter substrate chemotherapeutic drugs, and combine with anti-tumor drugs to enhance the curative effect effect. The effective dose of the compound is used in combination with an effective dose of an antineoplastic drug, including being mixed with an effective dose of an antineoplastic drug to prepare a pharmaceutically acceptable compound preparation, which is used for leukemia, lymphoma, gastric cancer, colon cancer, liver cancer, pancreatic cancer, etc. Cancer, breast cancer, nasopharyngeal cancer, cervical cancer, melanoma, multiple myeloma, sarcoma, including tumor treatment.

This invention relates to a human-derived bradeion protein having the following properties:[0001](i) it is a transmembranous protein;[0002](ii) it has a transmembranous portion, an extracellular portion, and a cytoplasmic portion in its molecule as determined by a hydrophobicity analysis according to Kyte-Doolittle method;[0003](iii) it is expressed in the human adult normal brain and heart, the expression level thereof in the heart being about 10% or lower of that in the brain, while it is not expressed in other adult normal organs of spleen, lung, liver, skeletal muscle, kidney and pancreas, and in fetal brain, lung, heart and kidney;[0004](iv) it induces programmed cell death when over-expressed in a cultured human brain-derived undifferentiated nerve cell line;[0005](v) it induces termination of cell division and aging when over-expressed in a cultured human brain-derived differentiated nerve cell;[0006](vi) it is located in cytoplasm in the course of the induced cell death, and forms an intracellular aggregate when overexpressed; and[0007](vii) it is expressed in a human colorectal cancer cell line or in a human malignant melanoma cell line, but not in leukemia, lymphoma and lung carcinoma,to a DNA encoding said bradeion protein, to a vector comprising said DNA, to a host cell comprising said vector, and to a method for detecting a cancer such as colorectal cancer or malignant melanoma.

The invention provides a kit for detecting lymphoid blood cancers (such as T / B lineage leukemia, lymphoma, myeloma minimal residual disease) developed based on high-throughput sequencing, the kit includes detecting IGH (VDJ), IGH (DJ), IGK, IGL, TCRβ, TCRγ, TCRδ, BCL1 / IGH, BCL2 / IGH multiplex PCR primer set with UMB (Unique Molecular Barcode, single molecule tag), House Keeping gene PCR primer pair, Multiplex PCR Mix (2X), internal reference DNA, Nuclease‑Free Water, Elution Buffer, and primers and index sequences required for high-throughput sequencing. Using the kit, newly mutated cancer cells can be found while detecting cancer cells, and by applying high-throughput sequencing technology combined with bioinformatics analysis, the detection sensitivity of MRD can detect at least one cancer cell in 1 million cells , which is 10 ‑6 (0.0001%), not only can quantitatively analyze the number of cancer cells to achieve the purpose of minimal residual disease detection, but also can correct sequence mutations caused by base mismatches generated by PCR amplification and sequence reading errors generated during library sequencing.

The invention relates to an application of beta-As4S4 in preparation of a medicine for treating hematological malignant tumors. The hematological malignant tumors are selected from leukemia, lymphoma, multiple myeloma, myelodysplastic syndrome, refractory anemia with increased immature cells, and refractory anemia during conversion into leukemia. The beta-As4S4 is stable and controllable in quality and can be wetted by water, and the wettability is superior to that of natural realgar. Meanwhile, compared with natural realgar, beta-As4S4 has better dissolubility in pure water and human gastrointestinal fluid, and has a better apoptosis induction effect on hematological malignant tumor cells.

The present invention relates to a method for predicting the risk of having the CLAD in a subject by measuring the expression level of TCL1A in a biological sample obtained from said subject. Inventors have used a large-scale gene expression profiling of whole blood cells to identify early biomarkers of BOS. Microarray experiments performed from 80 patients (40 stable (STA) and 40 BOS) identified 47 genes differentially expressed between STA and BOS recipients. An independent set of patients (13 STA, 11 BOS) was then used for external validation by qPCR. T-cell leukemia / lymphoma protein 1A (TCL1A) gene was identified and validated as a predictive marker of BOS more than 6 months before diagnosis with area under curve of 0.77. Accordingly, the invention relates to a method for predicting the risk of having the chronic lung allograft dysfunction (CLAD) and to a method for preventing the risk of having CLAD by administering immunosuppressive drugs.